233 related articles for article (PubMed ID: 8154880)
1. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons.
Uhl GR; Walther D; Mash D; Faucheux B; Javoy-Agid F
Ann Neurol; 1994 Apr; 35(4):494-8. PubMed ID: 8154880
[TBL] [Abstract][Full Text] [Related]
2. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease.
Joyce JN; Smutzer G; Whitty CJ; Myers A; Bannon MJ
Mov Disord; 1997 Nov; 12(6):885-97. PubMed ID: 9399211
[TBL] [Abstract][Full Text] [Related]
3. Subsets of midbrain dopaminergic neurons in monkeys are distinguished by different levels of mRNA for the dopamine transporter: comparison with the mRNA for the D2 receptor, tyrosine hydroxylase and calbindin immunoreactivity.
Haber SN; Ryoo H; Cox C; Lu W
J Comp Neurol; 1995 Nov; 362(3):400-10. PubMed ID: 8576447
[TBL] [Abstract][Full Text] [Related]
4. Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson's disease brains.
Counihan TJ; Penney JB
J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):164-9. PubMed ID: 9703165
[TBL] [Abstract][Full Text] [Related]
5. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
Hill WD; Arai M; Cohen JA; Trojanowski JQ
J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
[TBL] [Abstract][Full Text] [Related]
6. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra.
Howells DW; Porritt MJ; Wong JY; Batchelor PE; Kalnins R; Hughes AJ; Donnan GA
Exp Neurol; 2000 Nov; 166(1):127-35. PubMed ID: 11031089
[TBL] [Abstract][Full Text] [Related]
7. Dopamine transporter function assessed by antisense knockdown in the rat: protection from dopamine neurotoxicity.
Van Kampen JM; McGeer EG; Stoessl AJ
Synapse; 2000 Sep; 37(3):171-8. PubMed ID: 10881039
[TBL] [Abstract][Full Text] [Related]
8. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism.
Murray AM; Weihmueller FB; Marshall JF; Hurtig HI; Gottleib GL; Joyce JN
Ann Neurol; 1995 Mar; 37(3):300-12. PubMed ID: 7695230
[TBL] [Abstract][Full Text] [Related]
9. Reduced gene expression for dopamine biosynthesis and transport in midbrain neurons of adult male rats exposed prenatally to ethanol.
Szot P; White SS; Veith RC; Rasmussen DD
Alcohol Clin Exp Res; 1999 Oct; 23(10):1643-9. PubMed ID: 10549997
[TBL] [Abstract][Full Text] [Related]
10. Effect of MPTP-induced denervation on basal ganglia GABA(B) receptors: correlation with dopamine concentrations and dopamine transporter.
Calon F; Lavertu N; Lemieux AM; Morissette M; Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
Synapse; 2001 Jun; 40(3):225-34. PubMed ID: 11304760
[TBL] [Abstract][Full Text] [Related]
11. [Effect of electroacupuncture scalp point-through-point therapy on the expression of tyrosine hydroxylase and dopamine transporter mRNAs in substantia nigra of Parkinson's disease model rats].
Wang S; Qi XJ; Han D
Zhongguo Zhen Jiu; 2009 May; 29(5):391-4. PubMed ID: 19489498
[TBL] [Abstract][Full Text] [Related]
12. Chronic nicotine and smoking treatment increases dopamine transporter mRNA expression in the rat midbrain.
Li S; Kim KY; Kim JH; Kim JH; Park MS; Bahk JY; Kim MO
Neurosci Lett; 2004 Jun; 363(1):29-32. PubMed ID: 15157990
[TBL] [Abstract][Full Text] [Related]
13. ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia.
Galter D; Buervenich S; Carmine A; Anvret M; Olson L
Neurobiol Dis; 2003 Dec; 14(3):637-47. PubMed ID: 14678778
[TBL] [Abstract][Full Text] [Related]
14. Dopamine transporter (Dat) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson's disease.
Harrington KA; Augood SJ; Kingsbury AE; Foster OJ; Emson PC
Brain Res Mol Brain Res; 1996 Feb; 36(1):157-62. PubMed ID: 9011752
[TBL] [Abstract][Full Text] [Related]
15. Adrenalectomy counteracts the local modulation of astroglial fibroblast growth factor system without interfering with the pattern of 6-OHDA-induced dopamine degeneration in regions of the ventral midbrain.
Chadi G; Silva C; Maximino JR; Fuxe K; da Silva GO
Brain Res; 2008 Jan; 1190():23-38. PubMed ID: 18086466
[TBL] [Abstract][Full Text] [Related]
16. Environmental enrichment in adulthood eliminates neuronal death in experimental Parkinsonism.
Faherty CJ; Raviie Shepherd K; Herasimtschuk A; Smeyne RJ
Brain Res Mol Brain Res; 2005 Mar; 134(1):170-9. PubMed ID: 15790541
[TBL] [Abstract][Full Text] [Related]
17. Novel in vivo electrophysiological assay for the effects of cocaine and putative "cocaine antagonists" on dopamine transporter activity of substantia nigra and ventral tegmental area dopamine neurons.
Hinerth MA; Collins HA; Baniecki M; Hanson RN; Waszczak BL
Synapse; 2000 Dec; 38(3):305-12. PubMed ID: 11020233
[TBL] [Abstract][Full Text] [Related]
18. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC
Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497
[TBL] [Abstract][Full Text] [Related]
19. Enhanced glutamatergic phenotype of mesencephalic dopamine neurons after neonatal 6-hydroxydopamine lesion.
Dal Bo G; Bérubé-Carrière N; Mendez JA; Leo D; Riad M; Descarries L; Lévesque D; Trudeau LE
Neuroscience; 2008 Sep; 156(1):59-70. PubMed ID: 18706980
[TBL] [Abstract][Full Text] [Related]
20. Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons.
González-Hernández T; Barroso-Chinea P; De La Cruz Muros I; Del Mar Pérez-Delgado M; Rodríguez M
J Comp Neurol; 2004 Nov; 479(2):198-215. PubMed ID: 15452855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
